AstraZeneca reported strong Q4 and full year 2024 earnings, with product sales reaching $13.4 billion and total revenue at $14.9 billion, marking significant increases. The company's growth is attributed to successful Phase III trials and rising drug demand. CEO Pascal Soriot highlighted a promising future with new medicines and transformative technologies. Despite challenges, AstraZeneca's diverse revenue streams position it well for continued growth. Teljes cikk (Euronews.com)